Diabetes Drug Industry on the Verge of Development in the Coming Years

Image of Blog

Many pharmaceutical industries and companies develop, produce, discover, and market drugs for patients with different health disorders with the intention to cure them or reduce the symptoms. Currently, there is rapid growth in occurrence of numerous diseases over many regions worldwide. One of the most commonly observed diseases is diabetes.

What is Diabetes?

Diabetes is a disease that arises when blood glucose or blood sugar level rises too high. Blood glucose is a key source of energy that comes from the food that a person consumes. Insulin, a hormone made by the pancreas, helps the glucose from food to get into cells to produce energy. Sometimes, the body does not produce sufficient energy or any insulin, and then glucose remains in blood and doesn’t pass to cells. Overtime, having a greater amount of glucose in blood may cause severe health issues. 

According to the World Health Organization (WHO), around 422 million people all over the world had diabetes in 2014; it is observed mainly in people living in low-and middle-income countries. Moreover, nearly 1.6 million deaths are directly accredited to diabetes every year. Both the number of cases and the occurrence of diabetes have been gradually rising since the last few decades, which has augmented the demand for diabetes drugs. 

D:\Freelance\Company Data\Blogs\Diabetes Drugs Market\3775.jpg

Growing Developments in Diabetes Drugs

Mainly, diabetes is of different types such as type-1 diabetes, type-2 diabetes, and gestational diabetes. The main reason for the growing occurrence of diabetes is obesity. Many pharmaceutical companies and medical scientists have come up with several therapies and drugs to treat diabetes. For instance, in September 2019, Novo Nordisk received the U.S. Food and Drug Administration (FDA) approval for its oral type 2 diabetes drug, ‘Rybelsus.’ A once-daily GLP-1 (glucagon-like peptide-1) receptor agonist, which has been used since 2005 to treat type 2 diabetes patients. However, it’s a new day for patients with the oral form, as they typically have to inject their medications.

Impact of COVID-19 on Sales of Diabetes Drugs

Undoubtedly, the worry that COVID-19 impacts chronic heart, lung, and diabetic patients severely has made people buy more drugs for chronic disorders. Hence, a significant rise in the sales of diabetes drugs has been observed during the period, which is fuelling the market growth. For instance, according to our analysis, the sale of diabetes drugs in India rose to 18.2% in March 2020 as compared to 2019. However, the stoppage of drug manufacturing companies and unavailability of raw materials during lockdown has restricted the manufacturing of drugs during the COVID-19 pandemic.

Future Scenario of the Diabetes Drugs Market

Since last decade, the global diabetes drugs sector is increasing with a rapid pace; mainly due to growth in patient population and development and research done by competitors to fill the gaps in diabetes drug performance. For instance, in April 2019, Glenmark launched ‘Remogliflozin’, a globally researched novel anti-diabetes drug in India. Remogliflozin is a patent-protected and innovative sodium glucose co-transporter-2 inhibitor for type-2 diabetes mellitus treatment in adults. Moreover, in January, 2020, the research team from the Florey Institute of Neuroscience and Mental Health in Australia, has successfully developed a non-fibrillating form of human insulin to treat diabetes.


A number of drugs for different types of diabetes are accessible in the diabetes drug market; however, no available therapy can completely cure diabetes. As per a research by the U.S. postmenopausal females in 2016, people who smoked on an average 16.2 cigarettes each day demonstrated a 1.28-fold augmented risk of diabetes. Moreover, the WHO has projected that diabetes may lead to millions of deaths and it is the main cause of heart attack, blindness, stroke, lower limb amputation and kidney failure in the upcoming years. As a result, around 170 diabetes drugs are under the development stage to treat diabetes or conditions related to diabetes. 

Significant rise in interest of biopharmaceutical industries to develop certain drugs for diabetes due to growth in incidence of chronic diseases is expected to foster the market growth. For instance, according to the World Health Organization (WHO), the burden of chronic diseases is rapidly increasing across the globe. It has been estimated that by the end of 2020, the proportion of the burden of chronic diseases will rise up to 57%. To meet the increasing demand for medicines, governments of various countries are providing support to drug manufacturers, which is also expected to boost the growth of the diabetes drugs market in an upcoming year. However, strict regulatory rules, higher costs, and long approval period for drugs may decrease the growth of the diabetes drug market.  According to a study published by the University of Pittsburgh in January 2019, the price of ‘Lantus insulin’, used for the treatment of Type 1 and Type 2 diabetes has seen a 49% in recent years.


Recent Posts
Validation error occured. Please enter the fields and submit it again.